Zika Virus Clinical Trial
Official title:
Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome
Congenital Zika virus syndrome (SCZv) has been gaining attention in studies due to changes in the central nervous system and in the motor development of children. These changes resulted in an unexpected picture and without future predictability, with the appearance of several functional impairments and also on orthostatic posture. In this context, the protocol of orthostatism proposed here is a 10-week program of the use of a postural adjuster, the standing frame, made of its own with alternative material to the commercial models (cardboard). The use of low cost materials allows these devices to be made in the desired size without cost high, individually adapted, easy to be transported as it is light and can still be colored. It is an equipment that offers the opportunity to experience the orthostatic posture and mainly benefits children with little economic resources that enable the acquisition of traditional devices made of iron or wood and even imported equipment. The postural adjuster allows physical and sensorial opportunity, being an auxiliary resource in standing positioning, feasible for home use, besides being useful for performing functional activities. Thus, the objective will be to analyze the repercussions of the use of the standing frame on body alignment, muscle tone, gross motor function and gastrointestinal functions of children with SCZv. An uncontrolled intervention study will be conducted with children between 12 and 24 months of age, who will undergo an evaluation before use and after the use of the adjunct along with the proposed orthostatism protocol. The postural alignment will be evaluated through photogrammetry and the evaluation of muscle tone will be performed through the modified Tardieu scale. The Gross Motor Function Measure (GMFM) scale will be used to assess the gross motor function of the children involved in the study. Questionnaires will be applied for the collection of maternal socio-demographic data, the child's data, the type and time of therapy that the child already participates, and the gastrointestinal functions. Evaluations will occur in four moments: initial / before use, on the first day of placement in the adjuster, after the first month after use and after the second month of use. For statistical analysis, the Shapiro Wilk Test will be applied to evaluate the normality of the data, and the Friedman or ANOVA tests for repeated samples, to analyze intra-group time factor for the dependent variables of each individual.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04182685 -
Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
|
||
Enrolling by invitation |
NCT04398901 -
Neurodevelopmental Outcomes in ZIKV-Exposed Children
|
||
Completed |
NCT02996890 -
Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)
|
Phase 1 | |
Completed |
NCT03188731 -
ZIKAlliance Pregnant Women Cohort
|
||
Completed |
NCT03110770 -
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
|
Phase 2 | |
Active, not recruiting |
NCT04917861 -
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
|
Phase 2 | |
Completed |
NCT02794181 -
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
|
||
Recruiting |
NCT01099852 -
Cohort of Patients Infected by an Arbovirus
|
||
Completed |
NCT03611946 -
Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
|
Phase 1 | |
Completed |
NCT04064905 -
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
|
Phase 1 | |
Completed |
NCT03106714 -
Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil
|
||
Completed |
NCT02979938 -
Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection
|
||
Completed |
NCT03393286 -
ZIKAlliance Children Cohort (ZIKAllianceCH)
|
||
Completed |
NCT03425149 -
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT05123222 -
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
|
Phase 1 | |
Completed |
NCT02733796 -
Persistence of Zika Virus in Semen After Acute Infection
|
||
Completed |
NCT03014089 -
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT03263195 -
Prospective Cohort Study of HIV and Zika in Infants and Pregnancy
|
||
Withdrawn |
NCT03204409 -
ZIKAlliance Natural History Study
|